Pharmacogenomic testing now available in all 50 states
MASON, OHIO Jan. 24, 2012 – AssureRx Health, Inc., announced today that its laboratory has been certified by the New York State Department of Health, ensuring that patients throughout New York State have access to the GeneSightRx® testing program through their personal prescribing clinician. With the approval from New York State, the AssureRx Health laboratory is now certified to analyze DNA samples for pharmacogenomic testing in all 50 U.S. states.”New York has one of the most rigorous laboratory certifications in the country. We are extremely proud of our team’s accomplishment in such a short period of time”, said Donald R. Wright, executive vice president and COO of AssureRx Health. “This certification is a testimony to the high quality of our technology, laboratory team, and process”.
Clinicians in New York State who wish to offer GeneSightRx to their behavioral health patients can contact AssureRx Health directly and quickly register their practice to begin testing. Patients can only be tested with orders from a properly licensed and registered clinician.
About GeneSight
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.